In a groundbreaking revelation, the Global Parkinson’s Disease Industry is positioned to soar to unprecedented heights, with an estimated worth of US$5.41 Billion projected for the fiscal year 2023. This represents a substantial increase from the US$4.82 Billion recorded in 2022, marking a significant stride in the industry’s growth trajectory.
Parkinson’s disease, a complex neurological disorder characterized by the degeneration of nerve cells in specific brain regions, presents a multifaceted array of symptoms including rigidity, emotional fluctuations, cognitive impairments, and challenges in coordination and balance. Despite its formidable nature, the landscape of Parkinson’s treatment is evolving, with diverse therapeutic modalities including surgical interventions, pharmaceutical therapies, and cutting-edge medical approaches.
Request a Sample Copy of the Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-16241
When a patient’s medications are not functioning effectively, it can lead to an increase in Parkinson’s disease (PD) symptoms including tremor and walking problems, which is known as an “off episode.” In the US, NOURIANZ (istradefylline), an antagonist of the adenosine A2A receptor, is used for Parkinson’s disease. The medication offers patients with Parkinson’s disease a brand-new non-dopaminergic once-daily oral treatment alternative. Such developments are expected to spur global growth in the Parkinson’s disease market from 2023-2033.
Key Takeaways from the Global Parkinson’s Disease Industry Study
- The global Parkinson’s disease market is currently worth more than US$ 4.82 Billion.
- In 2023, the Carbidopa-levodopa segment by drug class type is expected to take the dominant market share of 32%.
- In 2023, considering the age type, the adult segment is predicted to gain a 21% market share.
- The North American market for Parkinson’s disease is predicted to grow with a steady CAGR of 12.5% from 2023-2033.
- The APAC for Parkinson’s disease is expected to grow with a steady CAGR of 12% during 2023-2033.
“The market is anticipated to expand as more drugs are approved for the treatment of Parkinson’s disease and as there is a robust pipeline of novel medications being developed for the condition.” comments a Future Market Insights analyst.
Discovering the assumptions behind the study. Ask an Analyst
https://www.futuremarketinsights.com/ask-question/rep-gb-16241
Competitive Landscape
Some of the top players in the Global Parkinson’s Disease Industry are:
- Sunovion Pharmaceuticals
- Adamas Pharmaceuticals
- Neurocrine Biosciences
- Supernus Pharmaceuticals
- Alectos Therapeutics
- Kyowa Kirin
- AbbVie
- Integrative Research Laboratories AB
- Annovis Bio Inc.
- Cerevel Therapeutics
- Biogen Inc.
- Amneal Pharmaceuticals
Some of the recent developments in this domain are:
- Biogen Inc. and Alectos Therapeutics signed an agreement in June 2022 to develop and market GBA2 inhibitors (AL01811), a possible therapy for Parkinson’s disease patients. This agreement grants Biogen worldwide rights to research, manufacture, and commercialize AL01811. They think they will be well-suited to assist in bringing AL01811 to patients who need it by combining Alectos’ experience in small-molecule therapies with Biogen’s worldwide development expertise in Parkinson’s disease. They are indeed energized by the prospect of using Biogen’s commercial skills to raise the standard of treatment in Parkinson’s disease as well as movement disorders in general.
Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-16241
More Valuable Insights Available
Future Market Insights, in its new offering, presents an unbiased analysis of the Parkinson’s disease Industry, presenting historical demand data (2018-2022) and forecast statistics from 2023 to 2033.
The study divulges essential insights on the market based on the Parkinson’s disease industry by type (juvenile parkinson disease, young-onset parkinson’s disease, idiopathic Parkinson disease), by age (adult and pediatric), by diagnosis (CT Scan, MRI Scan, DaTSCAN-SPECT scan, PET Scan), by drug class (carbidopa-levodopa, carbidopa-levodopa infusion, dopamine agonists, monoamine oxidase b inhibitors, catechol o-methyltransferase inhibitors, anticholinergics, amantadine) and regions.
Key Segments Covered In The Global Parkinson’s Disease Industry Report
Parkinson’s Disease Market By Type:
- Juvenile Parkinson Disease
- Young-Onset Parkinson’s Disease
- Idiopathic Parkinson Disease
Global Parkinson’s Disease Industry By Age:
- Adult
- Pediatric
Global Parkinson’s Disease Industry By Diagnosis:
- CT Scan
- MRI Scan
- DaTSCAN-SPECT scan
- PET Scan
Global Parkinson’s Disease Industry By Drug Class:
- Carbidopa-Levodopa
- Carbidopa-Levodopa Infusion
- Dopamine Agonists
- Monoamine Oxidase B Inhibitors
- Catechol O-Methyltransferase Inhibitors
- Anticholinergics
- Amantadine
Global Parkinson’s Disease Industry By Region:
- North America
- Latin America
- Eastern Europe
- Western Europe
- Asia-Pacific
- Middle East & Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
